Patent ID: 8278061
Filing Date: 2012-10-02
Classification: A61P,C12Q

Abstract:
1. A method for determining whether a human colorectal cancer patient is likely or less likely responsive to a single agent anti-EGFR antibody based therapy selected from Cetuximab or an antibody that binds to the same epitope that Cetuximab binds, comprising screening a suitable cell or tissue sample isolated from said patient for the genetic polymorphism of COX-2 T8473C SNP wherein the presence of the genetic polymorphism of (C/C) for COX-2 T8473C SNP indicates the patient is likely responsive to said single agent anti-EGFR antibody based therapy and wherein the absence of the genetic polymorphism of (C/C) for COX-2 T8473C SNP indicates the patient is less likely responsive to said single agent anti-EGFR antibody based therapy.